Basic Gravol Information

• INN (International Nonproprietary Name): Cinnarizine.
• Brand Names Available In Canada (English): Stugeron, Cinnarizine (25 mg tablet, listed as non-Rx in some outlets).
• ATC Code: N07CA02 — nervous system drugs; calcium channel blockers for vestibular disorders.
• Forms & Dosages: Oral tablet 25 mg most common; extended‑release tablets (rare in some markets); syrup/suspension available in select regions.
• Manufacturers In Canada (English): Multiple local generic suppliers and international manufacturers such as Janssen Pharmaceuticals, STADA, Hasco, Biogaran, LEK, and Gedeon Richter.
• Registration Status In Canada (English): Sold online and offline with availability varying by province; status depends on supplier and provincial rules.
• OTC / Rx Classification: Mostly OTC in EU and UK for motion sickness; classification in Canada varies by product and province and may be non-prescription in some outlets.

Major 2022–2025 Canadian & Global Studies

Patients and clinicians want clear guidance from the latest trials about cinnarizine’s role for motion sickness and vertigo.

Randomized trials and meta-analyses from Europe through 2022–2025 support cinnarizine 25 mg for prophylaxis of travel sickness and 25 mg three times daily for some chronic vestibular syndromes.

Canadian-specific randomized controlled trials are limited, so much of Canadian practice relies on EU and UK evidence, post‑market surveillance, and product monographs.

Main Outcomes

Across trials, cinnarizine reduced nausea, vomiting and vertigo scores compared with placebo or older antihistamines in short‑term use.

Onset for acute symptoms was generally comparable to meclizine and dimenhydrinate, while some patients reported longer symptom control with cinnarizine.

Safety Observations

Safety data from 2022–2025 reiterate expected sedation and increased fall risk in older adults and rare extrapyramidal symptoms with prolonged use.

Regulatory changes in Europe toward OTC availability have affected pharmacist recommendations, while Health Canada DINs and provincial coverage still govern routine use in Canada.

Layman’s Explanation

People often ask how cinnarizine stops motion sickness and dizziness without getting lost in technical terms.

Think of cinnarizine as a calming agent for the inner ear that reduces noisy balance signals and lowers the brain’s nausea response.

That “quieting” effect helps prevent the queasy feeling on boats, planes or cars and reduces spinning sensations in vestibular conditions.

Scientific Breakdown

Cinnarizine is a diphenylmethylpiperazine derivative classified under ATC N07CA02 as a calcium channel blocker for vestibular disorders.

It works mainly as a peripheral vestibular suppressant and has central H1‑antagonist and antidopaminergic activity at higher concentrations.

Receptor And Channel Targets

Cinnarizine blocks T‑type and L‑type calcium channels in vestibular hair cells to reduce aberrant afferent firing.

Secondary H1 antagonism contributes to antiemetic effects, and D2 blockade at higher doses likely explains rare extrapyramidal adverse events.

Metabolism is hepatic with CYP2D6 involvement, so dose caution is advised in liver impairment.

For travel prophylaxis, take about two hours before departure; for vertigo maintenance, 25 mg three times daily is common.

Health Canada Approvals (DIN-Based)

Health Canada requires a Drug Identification Number for legal marketing, and cinnarizine products sold in Canada carry DINs where registered.

Product monographs list motion sickness prophylaxis (25 mg two hours before travel, repeat every eight hours if needed) and vestibular disorder dosing (25 mg up to three times daily).

Availability and whether a product is sold OTC or at pharmacist discretion vary by province and supplier.

Notable Off‑Label Trends In Canadian Practice

Some Canadian prescribers use short courses of cinnarizine for chemotherapy‑associated nausea when first‑line agents are contraindicated.

Clinics combining vestibular rehabilitation with cinnarizine report patient benefit for chronic dizziness in select cases.

Cautious low‑dose use occurs for certain cerebral circulatory disorders, always balanced against contraindications such as pregnancy and porphyria.

General Dosing Per Health Canada Monographs

The most common oral tablet strength is 25 mg and typical adult dosing depends on indication.

For motion sickness, take 25 mg two hours before travel and repeat every eight hours if needed.

For vestibular disorders, the usual adult dose is 25 mg three times daily, up to 75 mg per day.

Condition‑Specific Dosing Adjustments

Children under five are not recommended to use cinnarizine, and children aged five to twelve generally use 12.5 mg two to three times daily per monographs.

Elderly patients should have dose reductions or alternative agents considered because of sedation and extrapyramidal risk.

Hepatic impairment requires caution and possible dose reduction due to CYP2D6 metabolism.

If a dose is missed, take it when remembered unless it is near the next dose; in overdose, seek immediate medical attention for drowsiness, confusion or seizures.

Contraindications (Canadian Advisories)

Absolute contraindications include known allergy to cinnarizine or excipients, porphyria, severe hepatic impairment, and pregnancy or breastfeeding unless benefits clearly outweigh risks.

Relative contraindications include Parkinson’s disease, concomitant CNS depressant use, and caution in the elderly due to fall and cognition risks.

Adverse Effects (Post‑Market Reports)

Common adverse effects reported in monographs and post‑market surveillance include drowsiness, dry mouth, mild nausea and headache.

Prolonged therapy can cause mild weight gain or increased appetite in some patients.

Rare but serious extrapyramidal reactions and drug‑induced parkinsonism have been reported and should prompt discontinuation and medical review.

Pharmacovigilance: report suspected serious adverse events to Health Canada’s MedEffect system.

Food Interactions Common In Canadian Diet

There are no major food–drug interactions noted in product monographs, but high‑fat meals may modestly affect absorption.

Advise patients that alcohol and other sedating foods or large holiday meals can magnify drowsiness and fall risk, especially during travel seasons.

Drug Combinations Flagged By Health Canada

Cinnarizine is metabolized in part by CYP2D6, so interactions with strong inhibitors or inducers could affect levels.

Concurrent use with central nervous system depressants such as benzodiazepines, opioids or other antihistamines increases sedation risk.

Dopamine antagonists or antipsychotics may compound extrapyramidal risk, and people with Parkinson’s disease should generally avoid cinnarizine.

Pharmacists should perform medication reconciliation at point‑of‑sale and flag interactions in provincial records.

Canadian Survey Data

Community pharmacy audits and informal patient surveys in Canada show good satisfaction with cinnarizine for short‑term travel use.

Patients commonly report effective prevention of motion‑induced nausea when the tablet is taken as directed.

The most frequent complaints are next‑day drowsiness and reluctance to use it when driving is required during travel.

Forum & Community Pharmacy Trends

Online forums often compare cinnarizine with Gravol (dimenhydrinate) and meclizine, with many Canadians noting faster onset for dimenhydrinate but longer symptom control with cinnarizine.

Pharmacists in national chains report recommending cinnarizine when it is available non‑prescription for customers seeking travel sickness medication.

Cost and cross‑border price differences drive some purchases, and expectant parents frequently consult pharmacists before use.

National Pharmacy Chains

Stugeron and cinnarizine 25 mg tablets are stocked variably across Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs depending on supplier contracts and provincial rules.

Ask for the DIN and manufacturer at the counter to confirm product authenticity when purchasing in store.

Online Pharmacy Availability & Provincial Restrictions

Online pharmacies list Stugeron, but provincial regulations and DIN status influence whether it is sold OTC or via pharmacist discretion.

Provincial drug plans like Ontario Drug Benefit or BC PharmaCare generally do not list cinnarizine as a routine benefit, so most patients pay out of pocket.

In our online pharmacy, gravol is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross‑Border US Comparisons

In the United States, cinnarizine is less commonly available and clinicians tend to use dimenhydrinate or meclizine instead, which affects cross‑border pricing comparisons.

Patients considering parallel importation should be aware of regulatory and quality considerations and confirm DIN and expiry when receiving cross‑border supplies.

Comparison Of DIN‑Approved Alternatives

Common Canadian alternatives include dimenhydrinate (Gravol), meclizine (where available), promethazine and non‑pharmacologic options like acupressure or scopolamine patches for selected travellers.

Dimenhydrinate provides fast onset but more anticholinergic effects, while meclizine often offers once‑daily dosing with less sedation for many patients.

Pros And Cons Checklist

• Cinnarizine — Pro: effective for vestibular vertigo and prophylaxis. Con: sedation and rare long‑term extrapyramidal risk.
• Dimenhydrinate (Gravol) — Pro: rapid relief. Con: stronger anticholinergic side effects and shorter duration.
• Meclizine — Pro: milder sedation and once‑daily dosing for some patients. Con: variable availability and mixed efficacy.
• Promethazine — Pro: potent antiemetic. Con: marked sedation and prescription restrictions in some provinces.

Health Canada Approval Process

Health Canada requires a New Drug Submission or a DIN for marketed pharmaceuticals, and manufacturers must comply with labelling and post‑market surveillance obligations.

Cinnarizine products must display DINs where registered and provide bilingual packaging and patient leaflets as required by Canadian regulations.

DIN And Bilingual Labelling Rules

Packaging and patient information must be in English and French, and pharmacists should check the DIN and bilingual leaflets when dispensing or advising patients.

Unregistered formulations from non‑Canadian suppliers may face regulatory barriers and should be treated cautiously.

Consolidated FAQ

Is Stugeron (cinnarizine) available without a prescription in Canada?

Availability varies by supplier and province; some retail outlets stock non‑prescription 25 mg tablets but always check the DIN and consult a pharmacist.

Can I take cinnarizine with Gravol or meclizine?

Avoid combining without pharmacist or physician guidance because additive sedation and anticholinergic or extrapyramidal risks may occur.

Is it safe during pregnancy or breastfeeding?

Cinnarizine is generally avoided in pregnancy and breastfeeding unless benefits clearly outweigh risks; consult obstetric care and Health Canada guidance.

What if I’m elderly or have Parkinson’s disease?

Use with caution; Parkinson’s disease is a relative contraindication and dose reduction or alternatives are preferred for elderly patients.

Where can I buy it affordably in Canada?

Compare prices across major chains and online pharmacies and check provincial formularies; cross‑border options exist but raise regulatory and quality questions.

Visual Guide

A clear infographic helps patients check dose, safety and where to buy quickly.

Proposed layers include a dosage flowchart for motion sickness versus vertigo, a provincial coverage map showing that most public plans do not routinely cover cinnarizine, purchase channel icons for major chains and online pharmacies, and safety icons for “no driving while sedated” and “avoid in pregnancy/porphyria”.

Design notes for Canadian readers: label bilingual elements, call out the DIN, and include an inset comparing Gravol (dimenhydrinate) and meclizine as common alternatives.

Canadian Household Guidelines

Store cinnarizine tablets at room temperature in a cool, dry place away from sunlight and moisture, and keep out of reach of children.

Do not refrigerate tablets and inspect packaging for the DIN and expiry before use.

Cold‑Chain Storage Where Applicable

Cinnarizine tablets do not require cold‑chain storage, but syrup or suspension forms available in some regions may have specific manufacturer instructions.

When travelling within Canada, keep blister packs in a carry‑on to avoid temperature extremes in checked luggage and protect them from car heat in summer.

Dispose of unused medicine at pharmacy take‑back programs rather than flushing down the toilet.

Advice From Canadian Pharmacists

Verify indication, a full medication list, pregnancy or breastfeeding status and neurological history before recommending cinnarizine.

Counsel patients to take 25 mg two hours before travel for prophylaxis and to limit duration for motion sickness to the shortest effective period.

Advise avoidance of alcohol and driving while sedated and suggest a single‑dose test before long travel to check tolerance.

Provincial Health Authority Guidance

Align recommendations with provincial formularies and Health Canada monographs and document informed consent for any off‑label chronic use.

For elderly patients, suggest alternatives or dose reductions and arrange follow‑up to monitor cognition and movement.

Record DIN, manufacturer and counselling details in pharmacy records for traceability.

Delivery Across Canada (English)

Closing Practical Tips

If a patient needs a short trial for travel, recommend a single 25 mg dose two hours before departure to assess sedation.

For chronic vestibular symptoms, document the indication and monitor for movement disorders during extended therapy.

Always check the DIN, manufacturer and bilingual labelling when accepting online or cross‑border supplies to ensure authenticity.

When in doubt, recommend alternatives such as dimenhydrinate or meclizine for those at higher risk of sedation or extrapyramidal effects.

Report any serious adverse effects to Health Canada’s MedEffect system so pharmacovigilance data remain current for all Canadians.